Table 1.

Characteristics of included trials

Study, Ref.	Country	Design	Total number of patients	Age (median/mean unless otherwise specified)	Proportion of RAS inhibitors use in the treatment group (%)	Mortality		Risk of bias
						RAS inhibitors users n/N; %)	Non-RAS inhibitors users (n/N; %)
Lopes et al. [11]	Brazil	Randomized, open-label trial	659	RAS inhibitor users = 56 (46.1–66.1) Non-RAS inhibitor users = 55 (46.1–63.1)	ACE inhibitor = 21.0 ARB = 79.0	9/334 (2.7)	9/325 (2.8)	Some concerns
Cohen et al. [12]	Global	Randomized, open-label trial	152	RAS inhibitor users = 62 (12) Non-RAS inhibitor users = 62 (12)	ACE inhibitor = 33.3 ARB = 66.7	11/75 (14.7)	10/77 (13.0)	Some concerns
Duarte et al. [13]	Argentina	Randomized, open-label trial	72	RAS inhibitor users = 63.8 (18.7) Non-RAS inhibitor users = 60.1 (17.8)	ARB (telmisartan 80 mg twice daily for 14 days) = 100	2/38 (5.3)	4/34 (11.8)	Some concerns
Nouri-Vaskeh et al. [14]	Iran	Randomized, double-blind, controlled trial	80	RAS inhibitor users = 67.3 (14.8) Non-RAS inhibitor users = 60.1 (17.3)	ARB (losartan 25 mg twice daily for at least 14 days) = 100	2/41 (4.9)	5/39 (12.8)	Some concerns